Apellis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLS research report →
About the company
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions.
- CEO
- Cedric Francois
- IPO
- 2017
- Employees
- 705
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $5.25B
- P/E
- 38.71
- P/S
- 4.75
- P/B
- 12.46
- EV/EBITDA
- 29.54
- Div Yield
- 0.00%
- Gross Margin
- 90.12%
- Op Margin
- 14.95%
- Net Margin
- 12.06%
- ROE
- 39.71%
- ROIC
- 18.11%
- Revenue
- $1.00B · 28.46%
- Net Income
- $22.39M · 111.31%
- EPS
- $0.18 · 111.25%
- Op Income
- $55.43M
- FCF YoY
- 151.00%
- 52W High
- $41.14
- 52W Low
- $16.61
- 50D MA
- $33.60
- 200D MA
- $26.15
- Beta
- -0.25
- Avg Volume
- 6.37M
Get TickerSpark's AI analysis on APLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Dunlop A. Sinclair | sell | 3,544 |
| May 14, 26 | Dunlop A. Sinclair | sell | 14,684 |
| May 14, 26 | Dunlop A. Sinclair | sell | 27,600 |
| May 14, 26 | Dunlop A. Sinclair | sell | 11,199 |
| May 14, 26 | Dunlop A. Sinclair | sell | 8,554 |
| May 14, 26 | Dunlop A. Sinclair | other | 161,567 |
| May 14, 26 | Dunlop A. Sinclair | sell | 7,441 |
| May 14, 26 | Dunlop A. Sinclair | sell | 27,600 |
| May 14, 26 | Dunlop A. Sinclair | sell | 5,748 |
| May 14, 26 | Chopas James George | other | 16,150 |
Our APLS coverage
Recent articles, reports, and earnings notes.
No research on APLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APLS report →Similar companies
Peers in the same neighborhood.